Clinical Trial Update: Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the efficacy and safety of T3D-959 in mild-to-moderate Alzheimer's disease subjects has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• T3D-959 (T3D-959)

Snippet

Sponsor: T3D Therapeutics, Inc. | Conditions: Alzheimer Disease | Phase 2 | Status: COMPLETED